Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma

Neurology: Genetics

Volumn 3, Issue 4, 2017, Pages

  Wrzeszczynski, Kazimierz O ^a   Frank, Mayu O ^a,f   Koyama, Takahiko ^b   Rhrissorrakrai, Kahn ^b   Robine, Nicolas ^a   Utro, Filippo ^b   Emde, Anne Katrin ^a   Chen, Bo Juen ^a,h   Arora, Kanika ^a   Shah, Minita ^a   Vacic, Vladimir ^a,i   Norel, Raquel ^b   Bilal, Erhan ^b   Bergmann, Ewa A ^a,j   Moore Vogel, Julia L ^a   Bruce, Jeffrey N ^c   Lassman, Andrew B ^c   Canoll, Peter ^c   Grommes, Christian ^d   Harvey, Steve ^e   Parida, Laxmi ^b   Michelini, Vanessa V ^e   Zody, Michael C ^a   Jobanputra, Vaidehi ^a,c   Royyuru, Ajay K ^b   Darnell, Robert B ^a,f,g   more..

^a NEW YORK GENOME CENTER   (United States)

^b IBM T J WATSON RESEARCH CENTER   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e IBM WATSON HEALTH   (United States)

^f Laboratory of Molecular Neuro oncology   (United States)

^g ROCKEFELLER UNIVERSITY   (United States)

^h GOOGLE INC   (United States)

ⁱ 23andMe Inc ^*  (United States)

^j MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DNA; LOMUSTINE; RNA; TEMOZOLOMIDE;

AGED; AGNOSIA; ARTICLE; BRAIN SURGERY; BRAIN TUMOR; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONTROLLED STUDY; DEATH; DETERIORATION; DNA DETERMINATION; DRUG IDENTIFICATION; GENE TARGETING; GENOME ANALYSIS; GENOMICS; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; INDEL MUTATION; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; PARIETAL LOBE; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TUMOR GENE; TUMOR GROWTH; TUMOR VOLUME; WALKING DIFFICULTY; WATSON GENOMIC ANALYTICS; WHOLE GENOME SEQUENCING;

EID: 85052665880     PISSN: None     EISSN: 23767839     Source Type: Journal    
DOI: 10.1212/NXG.0000000000000164     Document Type: Article

References (41)

1. Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL. Organizing knowledge to enable personalization of medicine in cancer. Genome Biol 2014; 15: 438.
2. Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. Cell Syst 2015; 1: 210-223.
3. Hyman DM, Solit DB, Arcila ME, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical nextgeneration sequencing enabling next-generation targeted therapy trials. Drug Discov Today 2015; 20: 1422-1428.
4. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
5. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134-1140.
6. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
7. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
8. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
9. Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequencequality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-Throughput sequencing datasets. Nucleic Acids Res 2012; 40: 11189-11201.
10. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
11. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 2009; 25: 2865-2871.
12. Narzisi G, O'Rawe JA, Iossifov I, et al. Accurate de novo and transmitted indel detection in exome-capture data using microassembly. Nat Methods 2014; 11: 1033-1036.
13. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012; 6: 80-92.
14. Aken BL, Ayling S, Barrell D, et al. The Ensembl gene annotation system. Database (Oxford) 2016; 2016: baw093.
15. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
16. Gene Ontology C. The Gene Ontology in 2010: extensions and refinements. Nucleic Acids Res 2010; 38: D331-D335.
17. Genomes Project C, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature 2015; 526: 68-74.
18. Xi R, Hadjipanayis AG, Luquette LJ, et al. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc Natl Acad Sci USA 2011; 108: E1128-E1136.
19. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012; 28: i333-i339.
20. Wang J, Mullighan CG, Easton J, et al. CREST maps somatic structural variation in cancer genomes with basepair resolution. Nat Methods 2011; 8: 652-654.
21. Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods 2009; 6: 677-681.
22. Emde AK, Schulz MH, Weese D, et al. Detecting genomic indel variants with exact breakpoints in single- And pairedend sequencing data using SplazerS. Bioinformatics 2012; 28: 619-627.
23. Ha G, Roth A, Khattra J, et al. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res 2014; 24: 1881-1893.
24. Van Loo P, Nordgard SH, Lingjaerde OC, et al. Allelespecific copy number analysis of tumors. Proc Natl Acad Sci USA 2010; 107: 16910-16915.
25. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29: 15-21.
26. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-930.
27. Risso D, Schwartz K, Sherlock G, Dudoit S. GC-content normalization for RNA-Seq data. BMC Bioinformatics 2011; 12: 480.
28. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
29. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
30. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
31. Rhrissorrakrai K, Koyama T, Parida L. Watson for genomics: moving personalized medicine forward. Trends Cancer 2016; 2: 392-395.
32. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128.
33. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015; 5: 850-859.
34. Navis AC, van Lith SA, van Duijnhoven SM, et al. Identification of a novel MET mutation in high-grade glioma resulting in an auto-Active intracellular protein. Acta Neuropathol 2015; 130: 131-144.
35. Backer JM. The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol 2010; 346: 87-114.
36. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009; 16: 463-474.
37. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol 2016; 34: 794-802.
38. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145.
39. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015; 7: 283ra253.
40. Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA 2015; 112: 5473-5478.
41. Turner TN, Hormozdiari F, Duyzend MH, et al. Genome sequencing of autism-Affected families reveals disruption of putative noncoding regulatory DNA. Am J Hum Genet 2016; 98: 58-74.